"The Retina Specialty Institute is the South’s #1 medical center for retinal and ophthalmology needs. With 13 state-of-the-art offices in Northwest Florida, Central Florida, Mississippi, and the Alabama Gulf Coast, getting quality retina care is more convenient than ever. Our well-trained and compassionate team have prevented blindness in over 1 million people. Let us help you achieve your best possible outcome!"

During the past decade, Retina Specialty Institute conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 18 clinical trials were completed, i.e. on average, 41.9% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 16 clinical trials were completed. i.e. 76.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Specialty Institute" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Genentech, Inc." with 7 trials sponsored, "Allergan" with 4 trials sponsored, "Kodiak Sciences Inc" with 4 trials sponsored and "Apellis Pharmaceuticals, Inc." with 4 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Specialty Institute" #1 collaborator was "Duke University" with 1 trials as a collaborator, "QLT Inc." with 1 trials as a collaborator, "Regeneron Pharmaceuticals" with 1 trials as a collaborator and "Trial Runners, LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Retina Specialty Institute" are "Geographic Atrophy" (12 trials), "Diabetic Macular Edema" (7 trials), "Macular Degeneration" (7 trials), "Neovascular Age-Related Macular Degeneration" (4 trials) and "Macular Edema" (3 trials). Many other conditions were trialed in "Retina Specialty Institute" in a lesser frequency.

Most popular intervention types in "Retina Specialty Institute" are "Drug" (43 trials), "Other" (14 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Aflibercept" (7 trials), "Faricimab" (5 trials), "Sham" (5 trials) and "KSI-301" (4 trials). Other intervention names were less common.

The vast majority of trials in "Retina Specialty Institute" are 47 trials for "All" genders.

Currently, there are NaN active trials in "Retina Specialty Institute". undefined are not yet recruiting, 5 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Retina Specialty Institute, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Specialty Institute, 5 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".